Sept 17 (Reuters) - A panel of expert outside advisers to the U.S. Food and Drug Administration voted on Friday to recommend COVID-19 vaccine booster shots for Americans 65 and older and those at high risk of illness, after rejecting a call for broader approval. (Reporting By Peter Henderson Editing by Bill Berkrot)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
121.9 USD | +0.68% | +9.36% | +22.56% |
May. 07 | UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating | MT |
May. 06 | News Highlights : Top Financial Services News of the Day - Monday at 4 PM ET | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B | |
+18.74% | 11.81B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna : U.S. FDA vaccine advisers vote in favor of COVID-19 booster shot for those 65 and older